Published in Health Qual Life Outcomes on November 26, 2010
Impact on the Incremental Cost-Effectiveness Ratio of Using Alternatives to EQ-5D in a Markov Model for Multiple Sclerosis. Pharmacoeconomics (2016) 1.00
Should linking replace regression when mapping from profile-based measures to preference-based measures? Value Health (2014) 0.98
Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients. Health Qual Life Outcomes (2012) 0.93
Predicting health utilities for children with autism spectrum disorders. Autism Res (2014) 0.92
A non-linear beta-binomial regression model for mapping EORTC QLQ- C30 to the EQ-5D-3L in lung cancer patients: a comparison with existing approaches. Health Qual Life Outcomes (2014) 0.81
Validation of the Fatigue Severity Scale in chronic hepatitis C. Health Qual Life Outcomes (2014) 0.80
Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma. Health Qual Life Outcomes (2015) 0.80
Mapping FACT-P to EQ-5D in a large cross-sectional study of metastatic castration-resistant prostate cancer patients. Qual Life Res (2014) 0.79
Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection. BMC Infect Dis (2014) 0.79
Mapping Functions in Health-Related Quality of Life: Mapping from Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L. Med Decis Making (2015) 0.78
Mapping and direct valuation: do they give equivalent EQ-5D-5L index scores? Health Qual Life Outcomes (2015) 0.78
Assessing the external validity of algorithms to estimate EQ-5D-3L from the WOMAC. Health Qual Life Outcomes (2016) 0.76
Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast Cancer Res Treat (2014) 0.76
Mapping of incontinence quality of life (I-QOL) scores to assessment of quality of life 8D (AQoL-8D) utilities in patients with idiopathic overactive bladder. Health Qual Life Outcomes (2014) 0.75
Mapping the EQ-5D index from the cystic fibrosis questionnaire-revised using multiple modelling approaches. Health Qual Life Outcomes (2015) 0.75
"Fibromyalgia and quality of life: mapping the revised fibromyalgia impact questionnaire to the preference-based instruments". Health Qual Life Outcomes (2017) 0.75
Longitudinal predictive ability of mapping models: examining post-intervention EQ-5D utilities derived from baseline MHAQ data in rheumatoid arthritis patients. Eur J Health Econ (2012) 0.75
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst (1993) 38.99
Modeling valuations for EuroQol health states. Med Care (1997) 21.66
The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol (2003) 4.53
A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ (2004) 4.42
The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ (2006) 3.27
The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes (2003) 3.04
A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ (2009) 2.91
The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res (1996) 2.53
Mapping the SF-12 to the EuroQol EQ-5D Index in a national US sample. Med Decis Making (2004) 1.75
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol (2003) 1.75
Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health (2008) 1.64
Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? Health Qual Life Outcomes (2009) 1.55
Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value Health (2009) 1.32
A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care (2004) 1.27
Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data. Value Health (2008) 1.23
Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. Arthritis Rheum (2007) 1.19
Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making (2009) 1.04
Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Health Econ (2010) 1.02
Work and sick leave among patients with early inflammatory joint conditions. Arthritis Rheum (2008) 0.98
Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Med Decis Making (2011) 0.96
Mapping MOS Sleep Scale scores to SF-6D utility index. Curr Med Res Opin (2007) 0.82
Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res (2005) 6.25
What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes (2003) 3.42
A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med (2005) 2.07
The impact of age-related macular degeneration on health status utility values. Invest Ophthalmol Vis Sci (2005) 1.91
Cost effectiveness of a community based exercise programme in over 65 year olds: cluster randomised trial. J Epidemiol Community Health (2004) 1.63
Improving the measurement of QALYs in dementia: developing patient- and carer-reported health state classification systems using Rasch analysis. Value Health (2011) 1.52
Estimating a preference-based index from the Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM): valuation of CORE-6D. Med Decis Making (2012) 1.51
Mapping between Visual Analogue Scale and Standard Gamble data; results from the UK Health Utilities Index 2 valuation survey. Health Econ (2006) 1.49
Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics (2002) 1.44
Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health (2013) 1.44
Modelling SF-6D health state preference data using a nonparametric Bayesian method. J Health Econ (2006) 1.40
A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. Med Care (2004) 1.27
Dear policy maker: have you made up your mind? A discrete choice experiment among policy makers and other health professionals. Int J Technol Assess Health Care (2010) 1.20
An assessment of the construct validity of the ASCOT measure of social care-related quality of life with older people. Health Qual Life Outcomes (2012) 1.18
The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis. Qual Life Res (2008) 1.14
Condition-specific preference-based measures: benefit or burden? Value Health (2012) 1.13
Estimating a preference-based index for a 5-dimensional health state classification for asthma derived from the asthma quality of life questionnaire. Med Decis Making (2010) 1.09
Populating an economic model with health state utility values: moving toward better practice. Value Health (2010) 1.09
Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res (2005) 1.08
The health care burden and societal impact of acute otitis media in seven European countries: results of an Internet survey. Vaccine (2010) 1.08
Finding legitimacy for the role of budget impact in drug reimbursement decisions. Int J Technol Assess Health Care (2009) 1.08
Best-worst scaling vs. discrete choice experiments: an empirical comparison using social care data. Soc Sci Med (2011) 1.07
Lead time TTO: leading to better health state valuations? Health Econ (2012) 1.05
Introducing the composite time trade-off: a test of feasibility and face validity. Eur J Health Econ (2013) 1.03
Physicians underestimate the importance of patient-centredness to patients: a discrete choice experiment in fertility care. Hum Reprod (2011) 1.02
Time trade-off: one methodology, different methods. Eur J Health Econ (2013) 1.00
Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. Health Qual Life Outcomes (2008) 0.98
Acceptability of less than perfect health states. Soc Sci Med (2005) 0.97
Using Rasch analysis to form plausible health states amenable to valuation: the development of CORE-6D from a measure of common mental health problems (CORE-OM). Qual Life Res (2010) 0.97
Comparison of the HUI3 with the SF-36 preference based SF-6D in a clinical trial setting. Value Health (2004) 0.96
The use of rasch analysis in reducing a large condition-specific instrument for preference valuation: the case of moving from AQLQ to AQL-5D. Med Decis Making (2010) 0.96
Developing preference-based health measures: using Rasch analysis to generate health state values. Qual Life Res (2010) 0.96
Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Med Decis Making (2011) 0.96
Preferences for long-term care services: willingness to pay estimates derived from a discrete choice experiment. Soc Sci Med (2010) 0.95
Estimating preference-based single index measures for dementia using DEMQOL and DEMQOL-Proxy. Value Health (2012) 0.95
US valuation of the SF-6D. Med Decis Making (2013) 0.94
The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Qual Life Res (2008) 0.94
Rasch analysis in the development of a simplified version of the National Eye Institute Visual-Function Questionnaire-25 for utility estimation. Qual Life Res (2011) 0.92
Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health (2011) 0.91
The valuation of the International Prostate Symptom Score (IPSS) for use in economic evaluations. Eur Urol (2002) 0.90
Modelling covariates for the SF-6D standard gamble health state preference data using a nonparametric Bayesian method. Soc Sci Med (2006) 0.88
Mapping the Functional Assessment of Cancer Therapy-general or -Colorectal to SF-6D in Chinese patients with colorectal neoplasm. Value Health (2012) 0.88
A randomised controlled trial and cost-effectiveness evaluation of "booster" interventions to sustain increases in physical activity in middle-aged adults in deprived urban neighbourhoods. BMC Public Health (2010) 0.87
Binary choice health state valuation and mode of administration: head-to-head comparison of online and CAPI. Value Health (2013) 0.86
The impact of adding an extra dimension to a preference-based measure. Soc Sci Med (2011) 0.86
A comparison of United States and United Kingdom EQ-5D health states valuations using a nonparametric Bayesian method. Stat Med (2010) 0.85
Assessing the introduction of universal varicella vaccination in the Netherlands. Vaccine (2006) 0.85
Time to tweak the TTO: results from a comparison of alternative specifications of the TTO. Eur J Health Econ (2013) 0.84
Inequalities in oncology care: Economic consequences of high cost drugs. Eur J Cancer (2006) 0.84
Impact of intravenous drug use on quality of life for patients with venous ulcers. J Adv Nurs (2007) 0.82
Health state utilities for skeletal-related events secondary to bone metastases. Eur J Health Econ (2013) 0.82
Multinational evidence of the applicability and robustness of discrete choice modeling for deriving EQ-5D-5L health-state values. Med Care (2014) 0.82
Examining the impact of 11 long-standing health conditions on health-related quality of life using the EQ-5D in a general population sample. Eur J Health Econ (2014) 0.82
Modeling SF-6D Hong Kong standard gamble health state preference data using a nonparametric Bayesian method. Value Health (2013) 0.81
A comparison of the discriminative and evaluative properties of the SF-36 and the SF-6D index. Qual Life Res (2011) 0.81
Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale. Eur J Health Econ (2011) 0.81
Estimating the SF-6D value set for a population-based sample of Brazilians. Value Health (2011) 0.80
Utility scores for the Health Utilities Index Mark 2: an empirical assessment of alternative mapping functions. Med Care (2005) 0.80
Predicting SF-6D from the European Organization for Treatment and Research of Cancer Quality of Life Questionnaire scores in patients with colorectal cancer. Value Health (2013) 0.80
The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework. Eur J Health Econ (2013) 0.79
Willingness to pay for lives saved by Helicopter Emergency Medical Services. Prehosp Emerg Care (2009) 0.79
The cost-effectiveness of treatment for congenital diaphragmatic hernia. J Pediatr Surg (2002) 0.78
The development of a QALY measure for epilepsy: NEWQOL-6D. Epilepsy Behav (2012) 0.78
Clustering Rasch results: a novel method for developing rheumatoid arthritis states for use in valuation studies. Value Health (2010) 0.78
From KIDSCREEN-10 to CHU9D: creating a unique mapping algorithm for application in economic evaluation. Health Qual Life Outcomes (2014) 0.78
Do Portuguese and UK health state values differ across valuation methods? Qual Life Res (2011) 0.77
A systematic review of health-related quality of life instruments used for people with venous ulcers: an assessment of their suitability and psychometric properties. J Clin Nurs (2010) 0.77
Common scale valuations across different preference-based measures: estimation using rank data. Med Decis Making (2013) 0.77
Predicting preference-based utility values using partial proportional odds models. BMC Res Notes (2014) 0.77
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. Value Health (2011) 0.76
The cost-effectiveness of an intensive treatment protocol for severe dyslexia in children. Dyslexia (2011) 0.76
Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health Qual Life Outcomes (2014) 0.76
A Portuguese value set for the SF-6D. Value Health (2010) 0.76
Impact of discussion on preferences elicited in a group setting. Health Qual Life Outcomes (2006) 0.75
Dealing with the health state 'dead' when using discrete choice experiments to obtain values for EQ-5D-5L heath states. Eur J Health Econ (2013) 0.75
Using mixed methods research to explore the effect of an adaptation exercise on general population valuations of health states. Qual Life Res (2011) 0.75
Exploring the consistency of the SF-6D. Value Health (2013) 0.75
Assessing current health-related quality of life questionnaires administered to patients with venous ulcers: can they be used in economic evaluations? J Clin Nurs (2010) 0.75
Perspectives of Clinicians Involved in the RESTART-Study: Outcomes of a Focus Group. Am J Speech Lang Pathol (2015) 0.75